

TECH TOUR SPECIAL JURY PRIZE 2017

BIO



Eamon Brady

Eamon has over 25 years MedTech experience and is founder and CEO of Neuravi a stroke interventional company that exited to JNJ in April 2017. Details of the exit to JNJ were not disclosed but the transaction was reported as the largest ever venture backed MedTech exit achieved by an Irish company and the largest venture backed MedTech exit in Europe in 8 years. Prior to Neuravi Eamon led international teams as both Global Director of R&D and Director of New Ventures at Abbott Vascular. He was a member of the founding team of MedNova Ltd., a company that pioneered embolic protection for carotid stenting, and helped lead the company to a \$100M acquisition by Abbott Vascular. Eamon has an engineering background and is a prolific inventor with over 200 US patents, granted or pending. He has a keen interest in all aspects of strategy, building teams and technology, innovation and patient care.

About Neuravi

Fully focused on improving acute stroke treatment, Neuravi develops and globally markets innovative medical devices for neurointerventional therapy that are based upon extensive research into the clot and occlusions that cause stroke. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics, in order to improve patient outcomes in stroke.